Oncology-New York最新文献_第4页

Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. 运动在癌症发生和发展过程中对炎症-免疫轴功能的调节作用

4区医学

Oncology-New York Pub Date : 2015-12-01

Graeme J Koelwyn, Erik Wennerberg, Sandra Demaria, Lee W Jones

引用次数: 0

Advances in the systemic treatment of metastatic melanoma. 转移性黑色素瘤的系统治疗进展。

4区医学

Oncology-New York Pub Date : 2013-05-01

Melinda Yushak, Harriet M Kluger, Mario Sznol

{"title":"Advances in the systemic treatment of metastatic melanoma.","authors":"Melinda Yushak, Harriet M Kluger, Mario Sznol","doi":"","DOIUrl":"","url":null,"abstract":"Prior to 2011, the only commercially available agents commonly used to treat metastatic melanoma-including dacarbazine, temozolomide (Temodar), fotemustine, carboplatin, paclitaxel, and interleukin-2-demonstrated limited efficacy, and no study involving these agents had shown an improvement in overall survival. The standard of care for the treatment of metastatic melanoma was radically changed by the subsequent approval of two agents, ipilimumab (Yervoy) and vemurafenib (Zelboraf), both of which improved survival in randomized phase III trials. Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes. Within this rich context of effective agents, the challenge for clinicians and investigators will be to develop predictive biomarkers of response, the optimal sequence of therapy for individual patients, and effective combinations. An additional challenge will be to find the appropriate venue and populations to test promising new agents arising from substantial advances in our understanding of molecular alterations in melanoma cells, of mechanisms of resistance to current agents, and of tumor-host immune interactions.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"27 5","pages":"374-81"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092183/pdf/nihms-982755.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milk thistle. 奶蓟草

4区医学

Oncology-New York Pub Date : 2008-10-01

Barrie Cassileth

引用次数: 0

Understanding and treating triple-negative breast cancer. 了解和治疗三阴性乳腺癌。

4区医学

Oncology-New York Pub Date : 2008-10-01

Carey Anders, Lisa A Carey

{"title":"Understanding and treating triple-negative breast cancer.","authors":"Carey Anders, Lisa A Carey","doi":"","DOIUrl":"","url":null,"abstract":"Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile, aggressive behavior, distinct patterns of metastasis, and lack of targeted therapies. Although not synonymous, the majority of triple-negative breast cancers carry the \"basal-like\" molecular profile on gene expression arrays. The majority of BRCA1-associated breast cancers are triple-negative and basal-like; the extent to which the BRCA1 pathway contributes to the behavior of sporadic basal-like breast cancers is an area of active research. Epidemiologic studies illustrate a high prevalence of triple-negative breast cancers among younger women and those of African descent. Increasing evidence suggests that the risk factor profile differs between this subtype and the more common luminal subtypes. Although sensitive to chemotherapy, early relapse is common and a predilection for visceral metastasis, including brain metastasis, is seen. Targeted agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly (ADP-ribose) polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"22 11","pages":"1233-9; discussion 1239-40, 1243"},"PeriodicalIF":0.0,"publicationDate":"2008-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0